MedTrace Logo

The Overall Survival of Patients With Unresectable HCC in Real-life

NCT03612726 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 5000

Last updated 2025-03-24

No results posted yet for this study

Summary

Liver cancer is the fifth most common cancer and the second most frequent cause of cancer-related death globally. Hepatocellular carcinoma represents about 90% of primary liver cancers and constitutes a major global health problem. The pattern of HCC occurrence shows a significant geographical imbalance, with the highest incidence rates in East Asia (more than 50% of the cases occurring in China).

The aim of this study is to investigate the overall survival (OS) of patients diagnosed with unresectable hepatocellular carcinoma under real-world practice conditions in Asia Pacific region.

Conditions

Sponsors & Collaborators

  • Tokyo University

    collaborator OTHER

  • Humanity & Health Medical Group Limited

    lead OTHER

Principal Investigators

  • Masao Omata, PhD, MD · Tokyo University

  • George Lau, MD · Humanity & Health Medical Group Limited

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-16
Primary Completion
2025-12-31
Completion
2025-12-31

Countries

  • China
  • Hong Kong
  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03612726 on ClinicalTrials.gov